Hello, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because that oh-so-familiar routine of meetings, deadlines, and conference calls has predictably returned. But you knew this would happen, yes? After all, the world keeps spinning. So what else to do but fire up the coffee kettle, brew a cup or three of stimulation, and dig in for another busy day. On that note, here are some items of interest to get you started. Hope you have a grand day and keep in touch. …

Pfizer (PFE) won Food and Drug Administration approval for an oral drug called tafamidis to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, Reuters says. Pfizer, which has touted the drug as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under the brand name Vyndaqel. It is the first medicine approved for the disease in the U.S., and analysts are forecasting annual sales to exceed $1 billion in 2024. Pfizer believes about 100,000 people in the U.S. have the condition, but most are not diagnosed.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy